BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-04-03
DOI
10.1093/neuonc/noaa084
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acromegaly
- (2019) Annamaria Colao et al. Nature Reviews Disease Primers
- The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
- (2018) Matthew P. Salomon et al. CLINICAL CANCER RESEARCH
- Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors
- (2018) Mahalakshmi Ramadoss et al. DRUG DISCOVERY TODAY
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Inhibition of Notch signaling attenuates pituitary adenoma growth in nude mice
- (2018) Lautaro Zubeldia-Brenner et al. ENDOCRINE-RELATED CANCER
- BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response inKras-Mutant Non–Small Cell Lung Cancer
- (2018) Dennis O. Adeegbe et al. Cancer Immunology Research
- Medical therapy for non-functioning pituitary tumors—a critical approach
- (2018) Metaxia Tampourlou et al. Hormones-International Journal of Endocrinology and Metabolism
- BRD4 and Cancer: going beyond transcriptional regulation
- (2018) Benedetta Donati et al. Molecular Cancer
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prognostic factors of regrowth in nonfunctioning pituitary tumors
- (2017) Gerald Raverot et al. Pituitary
- Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay
- (2017) Zhifeng Chen et al. MedChemComm
- Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for11C-dihydroergotamine during glyceryl trinitrate-induced migraine
- (2016) Christoph J. Schankin et al. BRAIN
- Landscape of Genomic Alterations in Pituitary Adenomas
- (2016) Wenya Linda Bi et al. CLINICAL CANCER RESEARCH
- Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
- (2016) Kjell Öberg et al. ENDOCRINE-RELATED CANCER
- Management of aggressive growth hormone secreting pituitary adenomas
- (2016) Daniel A. Donoho et al. Pituitary
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Recurrent gain-of-function USP8 mutations in Cushing's disease
- (2015) Zeng-Yi Ma et al. CELL RESEARCH
- Binding Kinetics versus Affinities in BRD4 Inhibition
- (2015) Ming Kuang et al. Journal of Chemical Information and Modeling
- Epidemiology and etiopathogenesis of pituitary adenomas
- (2014) Elena D. Aflorei et al. JOURNAL OF NEURO-ONCOLOGY
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Aggressive pituitary adenomas—diagnosis and emerging treatments
- (2014) Antonio Di Ieva et al. Nature Reviews Endocrinology
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Management of medically refractory prolactinoma
- (2013) Mark E. Molitch JOURNAL OF NEURO-ONCOLOGY
- MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells
- (2012) W.-J. Wang et al. CANCER RESEARCH
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Expression and Clinical Significance of Wnt Players and Survivin in Pituitary Tumours
- (2012) Robert Formosa et al. ENDOCRINE PATHOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair
- (2010) K. R. Luoto et al. CANCER RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Pathology of the human pituitary adenomas
- (2008) Robert Y. Osamura et al. HISTOCHEMISTRY AND CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now